ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

12 links0 made here, not in the record24 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT06743126SUPRAME-ACTengine® IMA203vs. Investigator's Choiceof Treatment in PreviouslyTreated, Unresectable orMetastatic CutaneousMelanomaImmatics US, Inc.Phase 3 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Oct 30 · ClinicalTrials.gov record · Version of 2026-10-30Version of 2026-10-30CONDITIONSMelanoma, Cutaneous Maligna…The registry's MeSH filing›Nov 14 · Rule based · Finest filed termAs of now · Rule based · Main conditionMain conditionDRUGSAnzutresgene autoleucelEntry “IMA203”, read by our name rule›Nov 1 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedNivolumabEntry “nivolumab plus relatlimab”, re…›Nov 1 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorRelatlimabEntry “nivolumab plus relatlimab”, re…›Nov 1 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorLifileucelIntervention entry›Nov 1 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorPembrolizumabIntervention entry›Nov 1 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorIpilimumabIntervention entry›Nov 1 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorDacarbazineIntervention entry›Nov 1 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorTemozolomideIntervention entry›Nov 1 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorPaclitaxelIntervention entry›Nov 1 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorCarboplatinEntry “paclitaxel plus carboplatin”, …›Nov 1 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorAlbumin-Bound PaclitaxelIntervention entry›Nov 1 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparator

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Anzutresgene autoleucel

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “IMA203”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Tested
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Oct 30The record itselfClinicalTrials.gov recordVersion of 2026-10-30Record change
Nov 1Anzutresgene autoleucelClaude Opus 5.5TestedCurrent
Nov 1NivolumabClaude Opus 5.5ComparatorCurrent
Nov 1RelatlimabClaude Opus 5.5ComparatorCurrent
Nov 1LifileucelClaude Opus 5.5ComparatorCurrent
Nov 1PembrolizumabClaude Opus 5.5ComparatorCurrent
Nov 1IpilimumabClaude Opus 5.5ComparatorCurrent
Nov 1DacarbazineClaude Opus 5.5ComparatorCurrent
Nov 1TemozolomideClaude Opus 5.5ComparatorCurrent
Nov 1PaclitaxelClaude Opus 5.5ComparatorCurrent
Nov 1CarboplatinClaude Opus 5.5ComparatorCurrent
Nov 1Albumin-Bound PaclitaxelClaude Opus 5.5ComparatorCurrent
Nov 14Melanoma, Cutaneous MalignantRule based · condition-kind ruleFinest filed termCurrent
Nov 18Anzutresgene autoleucelRule based · role ruleTestedAgrees
Nov 18NivolumabRule based · role ruleComparatorAgrees
Nov 18RelatlimabRule based · role ruleComparatorAgrees
Nov 18LifileucelRule based · role ruleComparatorAgrees
Nov 18PembrolizumabRule based · role ruleComparatorAgrees
Nov 18IpilimumabRule based · role ruleComparatorAgrees
Nov 18DacarbazineRule based · role ruleComparatorAgrees
Nov 18TemozolomideRule based · role ruleComparatorAgrees
Nov 18PaclitaxelRule based · role ruleComparatorAgrees
Nov 18CarboplatinRule based · role ruleComparatorAgrees
Nov 18Albumin-Bound PaclitaxelRule based · role ruleComparatorAgrees
As of nowMelanoma, Cutaneous MalignantRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.